Heineken response to GLP-1 medication impact

Heineken has advised British hospitality venues to prepare for potential revenue declines caused by the rising popularity of GLP-1 weight-loss medications, such as Ozempic and Wegovy.

The company identified two primary physiological risks: the medications slow gastric emptying, making large liquid volumes uncomfortable, and the active molecules may reduce alcohol cravings by affecting the brain’s reward circuits.

To mitigate these shifts in consumer behavior, Heineken recommends that pubs and bars offer smaller portions, such as half-pints, and expand their selection of low- or no-alcohol beverages. The company also suggests pairing drinks with small food plates to maintain revenue as consumers move toward more intentional, smaller-scale consumption patterns.

Recent industry presentations indicate that Heineken expects to continue monitoring these consumption shifts through 2027. Supporting market research from Circana highlights the potential scale of this impact; in the United States, households with at least one GLP-1 user spent approximately 7% less on alcohol and 13.5% less on beer per month compared to households without users. While some competitors, such as Carlsberg, have expressed caution regarding the direct causality of these trends, Heineken maintains that the physiological effects of the medication represent a significant business risk to traditional drinking culture.